Responses
Clinical/translational cancer immunotherapy
Original research
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
Compose a Response to This Article
Other responses
No responses have been published for this article.
